Long-term Beta-blocker Therapy After Acute Myocardial Infarction

The aim of the study is to determine whether discontinuation of β-blocker after at least 1 year of β-blocker therapy is noninferior to continuation of β-blocker in patients without heart failure (HF) or left ventricular systolic dysfunction after acute myocardial infarction (AMI). Prospective, open-label, randomized, multicenter, noninferiority trial to determine whether discontinuation of β-blocker after at least 1 year of β-blocker therapy is noninferior to continuation of β-blocker in patients without HF or left ventricular systolic dysfunction after AMI.

NCT Number	NCT04769362
Lead Sponsor	Samsung Medical Center Collaborators: Kangbuk Samsung Hospital, Gyeongsang National University Hospital, Kyung Hee University Hospital, Keimyung University Dongsan Medical Center, Korea University Anam Hospital, Sejong General Hospital, Seoul National University Bundang Hospital, Samsung Changwon Hospital, Saint Vincent's Hospital, Korea, Presbyterian medical center, Wonkwang University Hospital, Wonju Severance Christian Hospital, Ewha Womans University Seoul Hospital, Inje University Ilsan Paik Hospital, Chonbuk National University Hospital, Chonnam National University Hospital, Jeju National University Hospital, Chosun University Hospital, Chungbuk National University Hospital, Chungnam National University Hospital
Conditions	Myocardial Infarction
Enrollment	2,540 participants
Start Date	2021-05-04
Primary Completion	2026-01-31 (estimated)
Study Completion	2026-03-31 (estimated)
Updated on ClinicalTrials.gov	2025-12-29